December 16, 2008|
Another case of a potentially fatal brain infection has been reported in a patient taking the multiple sclerosis drug Tysabri, the biotech who developed the drug announced yesterday. This is the fourth case of infection, called progressive multifocal leukoencephalopathy (PML) this year. They are the only cases reported since the drug was taken off the market in 2005 because of three cases of infection. The FDA allowed Tysabri back on the market in 2006 with restrictions and stronger warnings.